Source comparison
Taper Protocols: Dose Reduction vs Frequency Reduction
The standard clinical taper for stopping tesamorelin + ipamorelin blend is a 2–4 week gradual reduction period. There are two approaches: dose reduction (lowering the amount per injection while maintaining frequency) and frequency reduction (maintaining dose b
This comparison does not assign a generated winner or score.
- The standard clinical taper for stopping tesamorelin + ipamorelin blend is a 2–4 week gradual reduction period. There are two approaches: dose reduction (lowering the amount per injection while maintaining frequency) and frequency reduction (maintaining dose but spacing injections further apart). Both work. The choice depends on your dosing schedule, baseline sensitivity, and how long you've been on the protocol.
- Dose reduction taper. If you've been using 1mg tesamorelin + 200mcg ipamorelin nightly, the taper looks like this: Week 1. Reduce to 0.75mg/150mcg nightly. Week 2. Reduce to 0.5mg/100mcg nightly. Week 3. Reduce to 0.25mg/50mcg nightly. Week 4. Stop. This approach maintains the circadian rhythm of nightly dosing (most secretagogues are dosed before bed to align with natural nocturnal GH pulses) while gradually reducing receptor stimulation. The pituitary receives progressively smaller exogenous signals, which allows endogenous GHRH and ghrelin production to increase proportionally as the taper progresses. Our clinical partners report this method produces the fewest subjective complaints during the transition. Patients notice a gradual softening of the peptide's effects rather than an abrupt drop-off.
- Frequency reduction taper. Maintain your full dose but extend the interval between injections. Week 1. Dose every other night instead of nightly. Week 2. Dose every third night. Week 3. Dose twice that week. Week 4. Stop. This method preserves the magnitude of each GH pulse but reduces the cumulative weekly exposure. It's particularly effective for patients who experienced strong acute responses (deep sleep, next-day recovery) and want to retain some of that benefit during the taper while still moving toward cessation. The downside: the on-and-off pattern can make it harder to assess whether symptoms during off days are taper-related or unrelated variables.
- Both protocols assume a 12+ week usage period. If you've only been on the blend for 4–6 weeks, a 1–2 week taper is sufficient. Receptor adaptation is less pronounced at shorter durations. If you've been on the protocol for six months or longer, extend the taper to 4–6 weeks and consider baseline IGF-1 testing before you start the taper and again at Week 4 post-cessation to confirm restoration.